GSK plc (GLAXF) stock
GLAXFOTCPharmaceutical PreparationsAlso trades as GSK
Financials through fiscal 2025, year ended Dec 31, 2025Score 9/30
$24.74+0.30 (+1.21%)
Close on Oct 19, 2026Market cap $106.83BP/E 13.3Yield –
GSK net income
Net income is the profit left for shareholders after every expense, interest and tax.
For fiscal 2025 it was £5.72B, up 122.0% from the year before. Over ten years it grew -3.8% a year on average. The highest annual figure on record is £14.96B in fiscal 2022.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | £5.72B | +122.0% |
| FY2024 | Dec 31, 2024 | £2.58B | -47.7% |
| FY2023 | Dec 31, 2023 | £4.93B | -67.1% |
| FY2022 | Dec 31, 2022 | £14.96B | +241.1% |
| FY2021 | Dec 31, 2021 | £4.39B | -23.7% |
| FY2020 | Dec 31, 2020 | £5.75B | +23.8% |
| FY2019 | Dec 31, 2019 | £4.65B | +28.2% |
| FY2018 | Dec 31, 2018 | £3.62B | +136.5% |
| FY2017 | Dec 31, 2017 | £1.53B | +68.0% |
| FY2016 | Dec 31, 2016 | £912.00M | -89.2% |
| FY2015 | Dec 31, 2015 | £8.42B | – |